Search results
New fathers should be screened for postpartum depression too, study says
Medical Xpress· 2 hours agoAn expanding volume of recent research has indicated that fathers, along with their female partners,...
Father of 2 opens up about 'period of darkness' while dealing with paternal postpartum depression
ABC7 News· 3 days agoAs we celebrate dads this weekend, we want to take the time to highlight an important, yet taboo,...
Mental Health Monday: dealing with post-partum depression
Black Hills FOX· 6 days agoPostpartum depression or PPD, also known as postnatal depression, is a mood disorder that can affect...
What to Know About Postpartum Hormones
Verywell Health via Yahoo News· 4 days agoAbout 50% to 80% of new parents have hormonal changes that cause what is referred to as the baby blues (sadness, mood swings, worry). But this typically...
Scotiabank maintains $19 target on Sage Therapeutics stock By Investing.com
Investing.com· 4 days agoThe endorsement follows a survey of 88 physicians that revealed strong recognition and satisfaction...
Bringing mental health resources to mothers in Georgia - Atlanta Business Chronicle
The Business Journals· 6 days agoBecoming a mother is a joyful experience, but for many moms, that joy can be eclipsed by postpartum depression and other mental health conditions. As a ...
Men Are Sharing The Things They Wish More People Knew About Fatherhood, And Wow, I Needed This
BuzzFeed via Yahoo News· 4 days ago"I’ve seen lots of posts from new dads freaking out and feeling like failures because they haven’t...
Caxton Associates LP Has $2.60 Million Stock Holdings in Sage Therapeutics, Inc. (NASDAQ:SAGE)
ETF DAILY NEWS· 5 days agoCaxton Associates LP boosted its holdings in shares of Sage Therapeutics, Inc. (NASDAQ:SAGE – Free Report) by 76.1% during the 4th quarter, according to its most recent disclosure with the Securities ...
Seven Eight Capital LP Decreases Stock Holdings in Sage Therapeutics, Inc. (NASDAQ:SAGE)
ETF DAILY NEWS· 5 days agoSeven Eight Capital LP lessened its stake in shares of Sage Therapeutics, Inc. (NASDAQ:SAGE – Free Report) by 51.0% during the 4th quarter, according to its most recent 13F filing with the SEC ...